• Something wrong with this record ?

HPMA Copolymer-Conjugated Pirarubicin in Multimodal Treatment of a Patient with Stage IV Prostate Cancer and Extensive Lung and Bone Metastases

H. Dozono, S. Yanazume, H. Nakamura, T. Etrych, P. Chytil, K. Ulbrich, J. Fang, T. Arimura, T. Douchi, H. Kobayashi, M. Ikoma, H. Maeda,

. 2016 ; 11 (1) : 101-6.

Language English Country France

Document type Case Reports, Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc17001088
E-resources Online Full text

NLK ProQuest Central from 2006-01-01 to 1 year ago
Medline Complete (EBSCOhost) from 2006-01-01 to 1 year ago
Nursing & Allied Health Database (ProQuest) from 2006-01-01 to 1 year ago
Health & Medicine (ProQuest) from 2006-01-01 to 1 year ago
Family Health Database (ProQuest) from 2006-01-01 to 1 year ago

Links

PubMed 26194363
DOI 10.1007/s11523-015-0379-4
Knihovny.cz E-resources

Nanomedicine allows achievement of tumor-selective drug delivery because of the enhanced permeability and retention (EPR) effect of solid tumors. We report here the first clinical application of a new agent-HPMA copolymer-conjugated pirarubicin (P-THP)-with a molecular size of about 8 nm, or 38.5 kDa. A patient had advanced prostate cancer with multiple metastases in the lung, pelvis, femur, and perhaps the sacrum. In April 2013, this 60-year-old patient started treatment with leuprorelin and estradiol, which continued until July 2014, but the patient became refractory to this treatment. So the patient underwent proton beam radiotherapy targeted to the primary prostate cancer, and P-THP was administered for numerous metastatic tumor nodules concomitantly with radiotherapy. This combination therapy had remarkable results, with complete remission of multiple metastases in the lung and bone. The prostate-specific antigen (PSA) value was decreased from about 1000 ng/mL on April 30, 2013, to about 100 ng/mL on June 24, 2013, with hormone therapy, but rose again to 964.2 ng/mL and then to 1472 ng/mL in July 2013, during leuprorelin administration. P-THP treatment administered concomitantly with proton beam irradiation was started in August 2013. The PSA value was decreased to 102 ng/mL on August 26, 2013, and then to 0.971 ng/mL on October 8, 2013, and 0.277 ng/mL on January 15, 2015. The P-THP doses ranged from 30 to 75 mg of free THP equivalent/patient every 2-3 weeks without signs of serious toxicity, such as cardiovascular side effects or a reduction in quality of life. No evidence of relapse was found more than 20 months after P-THP administration. This case demonstrates the value of hydrazone-bonded polymeric drugs in multimodal therapy.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17001088
003      
CZ-PrNML
005      
20170112114155.0
007      
ta
008      
170103s2016 fr f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s11523-015-0379-4 $2 doi
024    7_
$a 10.1007/s11523-015-0379-4 $2 doi
035    __
$a (PubMed)26194363
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a fr
100    1_
$a Dozono, Haruhiko $u Dozono Medical House, Kagoshima, Japan.
245    10
$a HPMA Copolymer-Conjugated Pirarubicin in Multimodal Treatment of a Patient with Stage IV Prostate Cancer and Extensive Lung and Bone Metastases / $c H. Dozono, S. Yanazume, H. Nakamura, T. Etrych, P. Chytil, K. Ulbrich, J. Fang, T. Arimura, T. Douchi, H. Kobayashi, M. Ikoma, H. Maeda,
520    9_
$a Nanomedicine allows achievement of tumor-selective drug delivery because of the enhanced permeability and retention (EPR) effect of solid tumors. We report here the first clinical application of a new agent-HPMA copolymer-conjugated pirarubicin (P-THP)-with a molecular size of about 8 nm, or 38.5 kDa. A patient had advanced prostate cancer with multiple metastases in the lung, pelvis, femur, and perhaps the sacrum. In April 2013, this 60-year-old patient started treatment with leuprorelin and estradiol, which continued until July 2014, but the patient became refractory to this treatment. So the patient underwent proton beam radiotherapy targeted to the primary prostate cancer, and P-THP was administered for numerous metastatic tumor nodules concomitantly with radiotherapy. This combination therapy had remarkable results, with complete remission of multiple metastases in the lung and bone. The prostate-specific antigen (PSA) value was decreased from about 1000 ng/mL on April 30, 2013, to about 100 ng/mL on June 24, 2013, with hormone therapy, but rose again to 964.2 ng/mL and then to 1472 ng/mL in July 2013, during leuprorelin administration. P-THP treatment administered concomitantly with proton beam irradiation was started in August 2013. The PSA value was decreased to 102 ng/mL on August 26, 2013, and then to 0.971 ng/mL on October 8, 2013, and 0.277 ng/mL on January 15, 2015. The P-THP doses ranged from 30 to 75 mg of free THP equivalent/patient every 2-3 weeks without signs of serious toxicity, such as cardiovascular side effects or a reduction in quality of life. No evidence of relapse was found more than 20 months after P-THP administration. This case demonstrates the value of hydrazone-bonded polymeric drugs in multimodal therapy.
650    _2
$a antitumorózní látky $x terapeutické užití $7 D000970
650    _2
$a nádory kostí $x sekundární $x terapie $7 D001859
650    _2
$a kombinovaná terapie $7 D003131
650    _2
$a doxorubicin $x analogy a deriváty $x terapeutické užití $7 D004317
650    12
$a systémy cílené aplikace léků $7 D016503
650    _2
$a lidé $7 D006801
650    _2
$a nádory plic $x sekundární $x terapie $7 D008175
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a methakryláty $x chemie $7 D008689
650    _2
$a lidé středního věku $7 D008875
650    _2
$a staging nádorů $7 D009367
650    _2
$a prognóza $7 D011379
650    _2
$a nádory prostaty $x patologie $x terapie $7 D011471
655    _2
$a kazuistiky $7 D002363
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Yanazume, Shintaro $u Department of Obstetrics and Gynecology, National Hospital Organization Kagoshima Medical Center, 8-1 Shiroyama, Kagoshima, 892-0853, Japan. s-yana@kagomc2.hosp.go.jp.
700    1_
$a Nakamura, Hideaki $u Institute of Drug Delivery Science, Sojo University, Ikeda 4-22-1, Nishi-ku, Kumamoto, 860-0082, Japan.
700    1_
$a Etrych, Tomáš $u Institute of Macromolecular Chemistry, Academy of Sciences, Prague, Czech Republic.
700    1_
$a Chytil, Petr $u Institute of Macromolecular Chemistry, Academy of Sciences, Prague, Czech Republic.
700    1_
$a Ulbrich, Karel $u Institute of Macromolecular Chemistry, Academy of Sciences, Prague, Czech Republic.
700    1_
$a Fang, Jun $u Institute of Drug Delivery Science, Sojo University, Ikeda 4-22-1, Nishi-ku, Kumamoto, 860-0082, Japan.
700    1_
$a Arimura, Takeshi $u Medipolis Proton Therapy and Research Center, Kagoshima, Japan. $7 gn_A_00008474
700    1_
$a Douchi, Tsutomu $u Department of Obstetrics and Gynecology, Kagoshima University School of Medicine, Kagoshima, Japan.
700    1_
$a Kobayashi, Hiroaki $u Department of Obstetrics and Gynecology, Kagoshima University School of Medicine, Kagoshima, Japan.
700    1_
$a Ikoma, Michiaki $u Ikoma Urology Clinic, Kagoshima, Japan.
700    1_
$a Maeda, Hiroshi $u Institute of Drug Delivery Science, Sojo University, Ikeda 4-22-1, Nishi-ku, Kumamoto, 860-0082, Japan. hirmaeda@ph.sojo-u.ac.jp.
773    0_
$w MED00189571 $t Targeted oncology $x 1776-260X $g Roč. 11, č. 1 (2016), s. 101-6
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26194363 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170103 $b ABA008
991    __
$a 20170112114255 $b ABA008
999    __
$a ok $b bmc $g 1180228 $s 961655
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 11 $c 1 $d 101-6 $i 1776-260X $m Targeted oncology $n Target Oncol $x MED00189571
LZP    __
$a Pubmed-20170103

Find record

Citation metrics

Archiving options